LILLY DRN
- U.S. News
Amgen stock falls as analysts mull over weight loss drug’s bone density data
Shares of Amgen fell more than 7% Tuesday as analysts chewed over bone density loss data from an early-stage trial…
Read More » - News
‘Two-stocks’ are better than one? Repacking ‘pair trades’
The exchange-traded fund industry is trying to make pair-trade strategies more accessible to everyday investors. Tidal Financial Group’s Michael Venuto…
Read More » - U.S. News
Eli Lilly’s Zepbound and Mounjaro are no longer in shortage. Here’s where their sales still disappointed
Eli Lilly’s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as…
Read More » - U.S. News
Novo Nordisk’s Ozempic and Wegovy now available in the U.S. after shortages, FDA says
Packages containing syringes of the medications Wegovy, Ozempic and Mounjaro at a shop in Mitte, Germany, July 11, 2024. Picture…
Read More » - U.S. News
Eli Lilly stock tumbles 10% after drug giant misses estimates and slashes profit guidance
Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023. Mike Blake | Reuters Eli Lilly on…
Read More » - U.S. News
Novo Nordisk’s diabetes drug Ozempic may reduce the risk of Alzheimer’s disease, study says
Steve Christo – Corbis | Corbis News | Getty Images Novo Nordisk‘s blockbuster diabetes drug Ozempic may reduce the risk…
Read More » - U.S. News
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
Novo Nordisk on Tuesday asked the Food and Drug Administration to prevent compounding pharmacies from making unapproved and often cheaper…
Read More » - News
Eli Lilly to trial use of weight loss drugs to combat unemployment in UK
LONDON — U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing…
Read More » - Europe
Novo and Lilly contender Zealand Pharma heralds its obesity drug alternative: It’s our ‘crown jewel’
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market dominated…
Read More » - U.S. News
Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
Eli Lilly will spend $4.5 billion to build a center aimed at finding better ways to manufacture its medicines. The…
Read More »
